SLC35G4: Key Enzyme in Fatty Acid Biosynthesis and Stress Protection

Target Name: SLC35G4

NCBI ID: G646000

SLC35G4

SLC35G4: Key Enzyme in Fatty Acid Biosynthesis and Stress Protection

SLC35G4, also known as Acyl-malonyl condensing enzyme 1-like 1, is a protein that is expressed in various tissues throughout the body. It is a key enzyme in the fatty acid biosynthesis pathway, which is involved in the production of essential fatty acids , including arachidonic acid, which is a pro-inflammatory compound that has been linked to various diseases, such as heart disease, cancer, and autoimmune disorders.

SLC35G4 is a 21-kDa protein that is expressed in various tissues, including muscle, heart, brain, and liver. It is primarily localized to the endoplasmic reticulum (ER) and is involved in the production of fatty acids, including arachidonic acid, which is produced through the condensation of omega-3 and omega-6 fatty acids.

SLC35G4 is a critical enzyme in the production of arachidonic acid, which is a pro-inflammatory compound that has been linked to various diseases, such as heart disease, cancer, and autoimmune disorders. Arachidonic acid is produced by the 20-lipoyl transacetylase (20 -LTA) enzyme, which is also encoded by the SLC35G4 gene. The 20-LTA enzyme is a key regulator of arachidonic acid production and is involved in the condensation of omega-3 and omega-6 fatty acids.

SLC35G4 is also involved in the production of other fatty acids, including omega-3 fatty acids, which are essential for various physiological processes, including brain function and eye health. In addition, SLC35G4 is involved in the production of docosahexaenoic acid (DHA), which is an important component of brain tissue and is associated with various cognitive functions.

SLC35G4 has also been shown to have anti-inflammatory properties and to protect against oxidative stress. It has been shown to reduce inflammation in various tissues, including mouse models of cancer and autoimmune disorders. In addition, SLC35G4 has been shown to protect against oxidative stress. in various cellular and animal models, including model endothelial cells and mice.

SLC35G4 is also expressed in various tissues and has been shown to be involved in various physiological processes, including fatty acid biosynthesis, inflammation, and stress protection. As a potential drug target or biomarker, SLC35G4 is a promising target for the development of new treatments for various diseases, including heart disease, cancer, and autoimmune disorders.

In conclusion, SLC35G4 is a critical enzyme involved in the production of arachidonic acid and other fatty acids. It has been shown to have anti-inflammatory and stress-protective properties and is a potential drug target or biomarker for the development of new treatments for various diseases. Further research is needed to fully understand the role of SLC35G4 in various physiological processes and to develop new treatments based on this protein.

Protein Name: Solute Carrier Family 35 Member G4

The "SLC35G4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC35G4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets